Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: NRM004
MIFTS: 51

Neuroma

Categories: Cancer diseases, Neuronal diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Neuroma

About this section

MalaCards integrated aliases for Neuroma:

Name: Neuroma 12 55 44 15 73

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:2001
MeSH 44 D009463
NCIt 50 C3275
UMLS 73 C0027858
Sources

Summaries for Neuroma

About this section
Disease Ontology : 12 A nervous system benign neoplasm that is characterized as a nerve tissue tumor.

MalaCards based summary : Neuroma is related to multiple mucosal neuroma and acoustic neuroma. An important gene associated with Neuroma is ANK3 (Ankyrin 3), and among its related pathways/superpathways are Developmental Biology and Neuroscience. The drugs Bupivacaine and Mepivacaine have been mentioned in the context of this disorder. Affiliated tissues include brain, bone and skin, and related phenotypes are Increased proliferation and behavior/neurological

Wikipedia : 76 A neuroma (/njʊəˈroʊmə/; plural: neuromata or neuromas) is a growth or tumor of nerve tissue. Neuromas... more...

Sources

Related Diseases for Neuroma

About this section

Diseases related to Neuroma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 248)
# Related Disease Score Top Affiliating Genes
1 multiple mucosal neuroma 34.1 ENO2 RET
2 acoustic neuroma 33.7 BICRA NF1 NF2 TGFB1
3 multiple endocrine neoplasia, type iib 32.7 CALCA GDNF RET
4 neurofibromatosis, type iv, of riccardi 32.6 NF1 NF2 RET
5 neurofibroma 30.4 NF1 NF2 S100B
6 laryngitis 30.2 FGF2 TGFB1
7 neurofibrosarcoma 30.2 NF1 NF2
8 ependymoma 30.0 ENO2 GFAP NF2 S100B
9 plexiform neurofibroma 30.0 ANK3 NF1 NF2
10 paine syndrome 29.7 NGF SCN10A TRPV1
11 medullomyoblastoma 29.3 ENO2 GFAP SMARCB1
12 multiple endocrine neoplasia 29.2 CALCA GDNF NF1 RET
13 thyroid carcinoma, familial medullary 29.2 CALCA ENO2 GDNF RET
14 malignant peripheral nerve sheath tumor 28.5 NF1 NF2 S100B SMARCB1
15 pheochromocytoma 27.8 CALCA ENO2 GDNF NF1 NGF RET
16 neurilemmoma 27.7 ENO2 GFAP NF1 NF2 S100B SMARCB1
17 neuroma biliary tract 11.9
18 neurofibromatosis, type ii 11.3
19 neurofibromatosis, type i 11.0
20 klumpke paralysis 11.0
21 lung meningioma 10.9 ENO2 NF2
22 cerebral convexity meningioma 10.9 GFAP NF2
23 meningothelial meningioma 10.9 ENO2 NF2
24 intraventricular meningioma 10.9 GFAP NF2
25 primitive neuroectodermal tumor of the cervix uteri 10.9 ENO2 GFAP
26 bednar tumor 10.9 ENO2 S100B
27 erb-duchenne and dejerine-klumpke palsies 10.9
28 gemistocytic astrocytoma 10.9 GFAP S100B
29 cerebellar medulloblastoma 10.8 ENO2 GFAP
30 fibrous meningioma 10.8 NF2 S100B
31 middle cerebral artery infarction 10.8 ENO2 S100B
32 ossifying fibromyxoid tumor 10.8 ENO2 S100B
33 central nervous system primitive neuroectodermal neoplasm 10.8 ENO2 GFAP
34 subependymal glioma 10.8 ENO2 GFAP
35 chordoid meningioma 10.8 GFAP S100B
36 syringocystadenoma papilliferum 10.8 GFAP S100B
37 benign ependymoma 10.8 ENO2 GFAP NF2
38 askin's tumor 10.8 ENO2 NGF
39 dysembryoplastic neuroepithelial tumor 10.7 GFAP S100B
40 spinal cancer 10.7 GFAP NF2
41 spindle cell rhabdomyosarcoma 10.7 GFAP S100B
42 chordoid glioma 10.7 GFAP NF2 S100B
43 intracranial cysts 10.7 ENO2 GFAP S100B
44 anaplastic ependymoma 10.7 GFAP NF2 S100B
45 clear cell ependymoma 10.7 ENO2 GFAP NF2
46 melanotic neuroectodermal tumor 10.7 ENO2 GFAP S100B
47 pineocytoma 10.7 ENO2 GFAP S100B
48 papillary ependymoma 10.7 ENO2 GFAP S100B
49 subependymal giant cell astrocytoma 10.7 ENO2 GFAP S100B
50 granular cell tumor 10.7 ENO2 GFAP S100B

Graphical network of the top 20 diseases related to Neuroma:



Diseases related to Neuroma
Sources

Symptoms & Phenotypes for Neuroma

About this section

GenomeRNAi Phenotypes related to Neuroma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased proliferation GR00094-A 8.62 NF2 SMARCB1

MGI Mouse Phenotypes related to Neuroma:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.4 TRPV1 GFAP ANK3 ENO2 NF1 FGF2
2 homeostasis/metabolism MP:0005376 10.23 TRPV1 NF2 GFAP NF1 FGF2 S100B
3 growth/size/body region MP:0005378 10.22 TGFB1 TRPV1 GDNF NF2 GFAP ENO2
4 cardiovascular system MP:0005385 10.21 TRPV1 GDNF GFAP NF1 FGF2 TGFB1
5 cellular MP:0005384 10.19 TGFB1 TRPV1 GDNF GFAP ENO2 FGF2
6 mortality/aging MP:0010768 10.14 TGFB1 GDNF ANK3 GFAP FGF2 NF1
7 nervous system MP:0003631 10.1 TRPV1 NF2 GFAP ANK3 ENO2 NF1
8 integument MP:0010771 10.03 TGFB1 TRPV1 NF2 NF1 S100B SCN10A
9 muscle MP:0005369 9.97 GDNF GFAP NF1 FGF2 TGFB1 NGF
10 neoplasm MP:0002006 9.87 TRPV1 NF2 NF1 FGF2 TGFB1 SMARCB1
11 renal/urinary system MP:0005367 9.7 TGFB1 TRPV1 GDNF ANK3 NF1 NF2
12 respiratory system MP:0005388 9.5 TGFB1 ANK3 ENO2 NF1 NF2 SCN10A
13 vision/eye MP:0005391 9.23 TGFB1 NF2 GFAP NF1 FGF2 SEMA3F
Sources

Drugs & Therapeutics for Neuroma

About this section

Drugs for Neuroma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 144)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bupivacaine Approved, Investigational Phase 4,Not Applicable 2180-92-9, 38396-39-3 2474
2
Mepivacaine Approved, Vet_approved Phase 4 96-88-8 4062
3
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
4 Anesthetics Phase 4,Phase 1,Not Applicable,Early Phase 1
5 Anesthetics, Local Phase 4,Phase 1,Not Applicable,Early Phase 1
6 Central Nervous System Depressants Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
7 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
8 Anti-Inflammatory Agents Phase 4,Phase 2,Not Applicable
9 glucocorticoids Phase 4,Not Applicable
10 Hormone Antagonists Phase 4,Not Applicable
11 Hormones Phase 4,Not Applicable
12 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Not Applicable
13 Anti-Infective Agents Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Immunosuppressive Agents Phase 4,Phase 2,Phase 1,Early Phase 1
15 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
16 Gentamicins Phase 4,Not Applicable
17 triamcinolone acetonide Phase 4
18 Triamcinolone diacetate Phase 4
19 Triamcinolone hexacetonide Phase 4
20
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
21
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
22
Mechlorethamine Approved, Investigational Phase 3,Phase 2 51-75-2 4033
23
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
24
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
25 Protein Kinase Inhibitors Phase 2, Phase 3,Early Phase 1
26 Alkylating Agents Phase 3,Phase 2,Phase 1
27 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Early Phase 1
28 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
29
Isophosphamide mustard Phase 3,Phase 2 0
30 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
31 Imatinib Mesylate Phase 2, Phase 3 220127-57-1 123596
32
Capsaicin Approved Phase 2,Phase 1 404-86-4 1548943
33
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
34
Mexiletine Approved, Investigational Phase 2 31828-71-4 4178
35
Morphine Approved, Investigational Phase 2 57-27-2 5288826
36
Everolimus Approved Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177
37
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
38
Sirolimus Approved, Investigational Phase 2,Phase 1,Early Phase 1 53123-88-9 5284616 6436030 46835353
39
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
40
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
41
Etoposide Approved Phase 2 33419-42-0 36462
42
Lenograstim Approved, Investigational Phase 2 135968-09-1
43
Acetylcholine Approved Phase 2,Not Applicable 51-84-3 187
44
Aspirin Approved, Vet_approved Phase 2 50-78-2 2244
45
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
46
nivolumab Approved Phase 2 946414-94-4
47
Pembrolizumab Approved Phase 2 1374853-91-4
48
Tacrolimus Approved, Investigational Phase 1, Phase 2 104987-11-3 445643 439492
49
Gemcitabine Approved Phase 2,Phase 1 95058-81-4 60750
50
Adenosine Approved, Investigational Phase 2 58-61-7 60961

Interventional clinical trials:

(show top 50) (show all 141)
# Name Status NCT ID Phase Drugs
1 Pathophysiology of Post Amputation Pain Completed NCT01632709 Phase 4 Bupivacaine;Placebo
2 A Comparative Post-marketing Study of Commercially Available Peripheral Nerve Gap Repair Options Completed NCT00948025 Phase 4
3 Blind and Ultrasound Guided Injection in Morton Neuroma Recruiting NCT03046108 Phase 4 blind injection of Mepivacaine;blind injection of Triamcinolone;guided injection of mepivacaine;guided injection of Triamcinolone
4 Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function Recruiting NCT02415257 Phase 4 Gentamicin
5 Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function Recruiting NCT02379754 Phase 4 Gentamicins
6 Stereotactic Radiation in Vestibular Schwannoma Unknown status NCT01449604 Phase 3
7 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
8 Cyberknife Radiosurgery for Patients With Neurinomas Recruiting NCT02055859 Phase 3
9 Vestibular Schwannoma - Radiosurgery or Expectation: V-REX. Recruiting NCT02249572 Phase 2, Phase 3
10 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
11 Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors Terminated NCT00427583 Phase 2, Phase 3 imatinib mesylate
12 A Study to Evaluate the Efficacy and Safety of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma) Completed NCT02283957 Phase 2 CNTX-4975
13 ALGRX 4975 in the Treatment of Patients With Morton's Neuroma Completed NCT00130962 Phase 2 ALGRX 4975
14 A Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma) Completed NCT02678793 Phase 2 CNTX-4975
15 Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) Completed NCT01207687 Phase 2
16 Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed NCT00973739 Phase 2 Lapatinib
17 Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2 Completed NCT00004437 Phase 2
18 Efficacy of Opioids and Mexiletine for the Treatment of Postamputation Pain Completed NCT00383682 Phase 2 morphine and mexiletine
19 Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed NCT02104323 Phase 2 Endostatin
20 Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients Completed NCT01490476 Phase 2 RAD001
21 Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 Completed NCT01419639 Phase 2 Everolimus (RAD001) , Afinitor®
22 Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01653028 Phase 2 Alisertib
23 Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Completed NCT01614795 Phase 2 Temsirolimus
24 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
25 Sorafenib and Dacarbazine in Soft Tissue Sarcoma Completed NCT00837148 Phase 2 Sorafenib and Dacarbazine
26 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors Completed NCT00304083 Phase 2 doxorubicin hydrochloride;etoposide;ifosfamide
27 S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor Completed NCT00068367 Phase 2 erlotinib hydrochloride
28 RGD PET/MRI in Sporadic Vestibular Schwannoma Recruiting NCT03393689 Phase 2 One injection of 68Ga-NODAGA-E[c(RGDyK)]2
29 Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma Recruiting NCT01199978 Phase 2
30 Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors Recruiting NCT02986919 Phase 2 CPI-0610
31 Study of Aspirin in Patients With Vestibular Schwannoma Recruiting NCT03079999 Phase 2 Aspirin;Placebo
32 Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas Recruiting NCT03231306 Phase 2 Binimetinib
33 Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Recruiting NCT02934256 Phase 2 Icotinib
34 Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas Recruiting NCT02129647 Phase 2 Axitinib
35 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Recruiting NCT03095248 Phase 2 Selumetinib
36 Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers Recruiting NCT03215511 Phase 1, Phase 2 LOXO-195
37 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
38 A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery Recruiting NCT02691026 Phase 2 Pembrolizumab
39 Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Recruiting NCT02601209 Phase 1, Phase 2 Pazopanib Hydrochloride;Sapanisertib
40 PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors Recruiting NCT02584647 Phase 1, Phase 2 PLX3397;Sirolimus
41 Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting NCT02584309 Phase 2 Dexrazoxane;Doxorubicin;Olaratumab
42 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2 Gemcitabine Hydrochloride;Pazopanib Hydrochloride
43 Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma Active, not recruiting NCT01345136 Phase 2 RAD001, everolimus
44 Axillary Reverse Mapping Active, not recruiting NCT00572481 Phase 2
45 AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas Active, not recruiting NCT02831257 Phase 2 AZD2014
46 Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas Active, not recruiting NCT01767792 Phase 2 Bevacizumab
47 Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas Active, not recruiting NCT01125046 Phase 2
48 Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma Active, not recruiting NCT02452554 Phase 2
49 SARC023: Ganetespib and Sirolimos in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors) Active, not recruiting NCT02008877 Phase 1, Phase 2 ganetespib;Sirolimus
50 SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors Active, not recruiting NCT01661283 Phase 2 everolimus;bevacizumab

Search NIH Clinical Center for Neuroma

Cochrane evidence based reviews: neuroma

Sources

Genetic Tests for Neuroma

About this section
Sources

Anatomical Context for Neuroma

About this section

MalaCards organs/tissues related to Neuroma:

41
Brain, Bone, Skin, Testes, Liver, Tongue, Thyroid
Sources

Publications for Neuroma

About this section

Articles related to Neuroma:

(show top 50) (show all 1064)
# Title Authors Year
1
Risk of posterior semicircular canal trauma when using a retrosigmoid approach for acoustic neuroma surgery and role of endoscopy: An imaging study. ( 29493720 )
2018
2
Painful Terminal Neuroma Prevention by Capping PRGD/PDLLA Conduit in Rat Sciatic Nerves. ( 29938170 )
2018
3
Acoustic Neuroma Treated with Stereotactic Radiosurgery: Follow-up of 335 Patients. ( 29715569 )
2018
4
Mechanical Metatarsalgia as a Risk Factor for Relapse of Morton's Neuroma After Ultrasound-Guided Alcohol Injection. ( 29779991 )
2018
5
Patient Decision Making in Vestibular Schwannoma: A Survey of the Acoustic Neuroma Association. ( 29436268 )
2018
6
Superficial Peroneal Nerve to Deep Peroneal Nerve Transfer With Allograft Conduit for Neuroma in Continuity. ( 29685562 )
2018
7
Nonspecific Chronic Anteromedial Knee Pain Neuroma as a Cause of Infrapatellar Pain Syndrome: Case Study and Literature Review. ( 29404377 )
2018
8
Solitary Circumscribed Neuroma: Dermoscopic clues to facilitate diagnosis. ( 29666696 )
2018
9
Increased sensibility to acute acoustic and blast trauma among patients with acoustic neuroma. ( 29184217 )
2018
10
Risk factors and the associated cutoff values for failure of corticosteroid injection in treatment of Morton's neuroma. ( 29230531 )
2018
11
Plantar Pressure Measurements and Geometric Analysis of Patients With and Without Morton's Neuroma. ( 29641258 )
2018
12
Cochlea-sparing acoustic neuroma treatment with 4I8 radiation therapy. ( 29904732 )
2018
13
Increased Hospital Surgical Volume Reduces Rate of 30- and 90-Day Readmission After Acoustic Neuroma Surgery. ( 29889284 )
2018
14
Acoustic neuroma quality of life: are we missing the point? ( 29948270 )
2018
15
The medium and long-term effect of electrophysiologic monitoring on the facial nerve function in minimally invasive surgery treating acoustic neuroma. ( 29563978 )
2018
16
Epithelial sheath neuroma with extension to the subcutis. ( 29797343 )
2018
17
Long-term outcome after Gamma Knife radiosurgery for acoustic neuroma of all Koos grades: a single-center study. ( 29498575 )
2018
18
Painful Neuroma Treatment of the Supraorbital Nerve and Forehead Neurotization Using Human Cadaveric Nerve Allograft. ( 29521743 )
2018
19
Neuroma Implantation into Long Bones: Clinical Foundation for a Novel Osseointegrated Peripheral Nerve Interface. ( 29922565 )
2018
20
Ophthalmic Complications Following Acoustic Neuroma Resection. ( 29253289 )
2018
21
Endobronchial Mucosal Neuroma with Sarcoidosis. ( 29394980 )
2018
22
The impact of acoustic neuroma on long-term quality-of-life outcomes in the United Kingdom. ( 29330600 )
2018
23
Bilateral Nonsynchronous Pacinian Corpuscle Neuroma. ( 29627280 )
2018
24
Regenerative Peripheral Nerve Interface for Management of Postamputation Neuroma. ( 29847613 )
2018
25
Pediatric Multiple Endocrine Neoplasia Type 2B: Clinicopathological Correlation of Perilimbal Mucosal Neuromas and Treatment of Secondary Open-Angle Glaucoma. ( 29765955 )
2018
26
Novel experimental surgical strategy to prevent traumatic neuroma formation by combining a 3D-printed Y-tube with an autograft. ( 29424651 )
2018
27
Analysis of regeneration- and myelination-associated proteins in human neuroma in continuity and discontinuity. ( 29656327 )
2018
28
Incidence and associations of painful neuroma in a contemporary cohort of lower-limb amputees. ( 29654613 )
2018
29
Transcanal Transpromontorial Acoustic Neuroma Surgery: Results and Facial Nerve Outcomes. ( 29227438 )
2018
30
Operative Mortality Rates of Acoustic Neuroma Surgery: A National Cancer Database Analysis. ( 28187056 )
2017
31
Post-transplant Amputation Traumatic Neuroma of the Hilum and Extrahepatic Duct in a Liver Donor. ( 28774160 )
2017
32
Intravenous Glomus Tumor Masquerading as Lateral Antebrachial Cutaneous Neuroma. ( 28344537 )
2017
33
Validation of the facial dysfunction domain of the Penn Acoustic Neuroma Quality-of-Life (PANQOL) Scale. ( 28391530 )
2017
34
The Top 50 Most-Cited Articles on Acoustic Neuroma. ( 29288105 )
2017
35
Evaluation of Auditory Pathways Using DTI in Patients Treated with Gamma Knife Radiosurgery for Acoustic Neuroma: AA Preliminary Report. ( 28258282 )
2017
36
Three Cycles of Radiofrequency Ablation Are More Efficacious Than Two in the Management of Morton's Neuroma. ( 28513218 )
2017
37
Arytenoid neuromas are a recognized feature of SOS1 mutations causing pure mucosal neuroma syndrome. ( 28863001 )
2017
38
Postablation neuroma of the myometrium - a report of 5 cases. ( 28843713 )
2017
39
The sodium-channel blocker lidocaine in subanesthetic concentrations reduces spontaneous and evoked pain in human painful neuroma. ( 29911611 )
2017
40
Postoperative Headache after Undergoing Acoustic Neuroma Surgery via the Retrosigmoid Approach. ( 29021412 )
2017
41
Influencing Factors Analysis of Facial Nerve Function after the Microsurgical Resection of Acoustic Neuroma. ( 28264236 )
2017
42
Conservative treatment of vestibular schwannoma: growth and Penn Acoustic Neuroma Quality of Life scale in French language. ( 28872162 )
2017
43
Pacinian Corpuscles Neuroma. An Exceptional Cause of Pain in the Hand. ( 28506166 )
2017
44
Multistep translation and cultural adaptation of the Penn acoustic neuroma quality-of-life scale for German-speaking patients. ( 28861705 )
2017
45
Impact of insurance status and race on receipt of treatment for acoustic neuroma: A national cancer database analysis. ( 28343920 )
2017
46
Morton's interdigital neuroma of the foot: A literature review. ( 29409221 )
2017
47
Peripheral Neuromodulation for the Treatment of Postamputation Neuroma Pain: A Case Report. ( 27828784 )
2017
48
Pro and anti-inflammatory cytokine levels (TNF-I+, IL-1I^, IL-6 and IL-10) in rat model of neuroma. ( 28462800 )
2017
49
Probabilistic Multiple-Bias Modeling Applied to the Canadian Data From the Interphone Study of Mobile Phone Use and Risk of Glioma, Meningioma, Acoustic Neuroma, and Parotid Gland Tumors. ( 28535174 )
2017
50
Morton's Neuroma (Interdigital Neuralgia) Treated with Metatarsal Sliding Osteotomy. ( 29200487 )
2017
Sources

Variations for Neuroma

About this section
Sources

Expression for Neuroma

About this section
Search GEO for disease gene expression data for Neuroma.
Sources

Pathways for Neuroma

About this section

Pathways related to Neuroma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Developmental Biology 66
Show member pathways
 13.01 ANK3 FGF2 GDNF NF1 RET SCN10A
2
Neuroscience 4
11.81 CALCA ENO2 GFAP NF1 NF2 NGF
3
Spinal Cord Injury 1
11.58 GDNF GFAP TGFB1
4
Neural Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.25 FGF2 GDNF GFAP NGF S100B
5
Lung fibrosis 1
11.13 CALCA FGF2 TGFB1
Sources

GO Terms for Neuroma

About this section

Cellular components related to Neuroma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dendrite GO:0030425 9.55 ANK3 NF1 NGF RET TRPV1
2 neuronal cell body GO:0043025 9.43 CALCA ENO2 RET S100B TGFB1 TRPV1
3 axon GO:0030424 9.1 ANK3 CALCA NF1 NGF RET TGFB1

Biological processes related to Neuroma according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.85 CALCA FGF2 GDNF NGF TGFB1
2 negative regulation of cell proliferation GO:0008285 9.83 NF1 NF2 NGF SMARCB1 TGFB1
3 positive regulation of apoptotic process GO:0043065 9.72 NF1 NGF S100B TGFB1 TRPV1
4 wound healing GO:0042060 9.69 FGF2 NF1 TGFB1
5 negative regulation of DNA replication GO:0008156 9.6 NF2 TGFB1
6 negative regulation of cell-matrix adhesion GO:0001953 9.59 NF1 NF2
7 positive regulation of branching involved in ureteric bud morphogenesis GO:0090190 9.58 GDNF TGFB1
8 sympathetic nervous system development GO:0048485 9.58 GDNF NF1
9 hyaluronan catabolic process GO:0030214 9.57 FGF2 TGFB1
10 nerve development GO:0021675 9.56 NGF SEMA3F
11 detection of temperature stimulus involved in sensory perception of pain GO:0050965 9.55 CALCA TRPV1
12 negative regulation of cell-cell adhesion GO:0022408 9.54 NF2 TGFB1
13 ureteric bud development GO:0001657 9.54 GDNF RET TGFB1
14 lens fiber cell differentiation GO:0070306 9.52 NF2 TGFB1
15 positive regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001241 9.49 NF1 RET
16 enteric nervous system development GO:0048484 9.48 GDNF RET
17 neural crest cell migration GO:0001755 9.43 GDNF RET SEMA3F
18 negative regulation of neuroblast proliferation GO:0007406 9.4 NF1 TGFB1
19 MAPK cascade GO:0000165 9.35 FGF2 GDNF NF1 RET TGFB1
20 peripheral nervous system development GO:0007422 9.33 GDNF NF1 NGF
21 response to pain GO:0048265 8.8 CALCA RET TRPV1

Molecular functions related to Neuroma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.86 ANK3 BICRA CALCA ENO2 FGF2 GDNF
2 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.33 FGF2 GDNF RET
3 growth factor activity GO:0008083 8.92 FGF2 GDNF NGF TGFB1
Sources

Sources for Neuroma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....